| Literature DB >> 34108344 |
Shin Takayama1,2,3, Ryutaro Arita1,2, Rie Ono1,2, Natsumi Saito1,2, Satoko Suzuki1,2, Akiko Kikuchi1,2,3, Minoru Ohsawa1,2,3, Yasunori Tadano2, Tetsuya Akaishi2, Junichi Tanaka2, Takeshi Kanno2, Michiaki Abe2, Ko Onodera2, Tadashi Ishii1,2,3.
Abstract
Olfactory disorders are one of the characteristic symptoms of the coronavirus disease of 2019 (COVID-19), which causes infection and inflammation of the upper and lower respiratory tract. To our knowledge, there are no treatments for COVID-19-related olfactory disorder. Here, we report five olfactory disorder cases in COVID-19, treated using the Japanese traditional (Kampo) medicine, kakkontokasenkyushin'i. We treated five patients with mild COVID-19 at an isolation facility using Kampo medicine, depending on their symptoms. Patients with the olfactory disorder presented with a blocked nose, nasal discharge or taste impairment. Physical examination using Kampo medicine showed similar findings, such as a red tongue with red spots and sublingual vein congestion, which presented as blood stasis and inflammation; thus, we prescribed the Kampo medicine, kakkontokasenkyushin'i. After administration, the numeric rating scale scores of the smell impairment improved within 3 days from 9 to 3 in case 1, from 10 to 0 in case 2, from 9 to 0 in case 3, from 5 to 0 in case 4, and from 9 to 0 within 5 days in case 5. Following the treatment, other common cold symptoms were also alleviated. Kakkontokasenkyushin'i can be used for treating nasal congestion, rhinitis, and inflammation in the nasal mucosa. The olfactory disorder in COVID-19 has been reportedly associated with inflammation and congestion, especially in the olfactory bulb and olfactory cleft. Kakkontokasenkyushin'i may be one of the treatment alternatives for the olfactory disorder with rhinitis in patients with COVID-19.Entities:
Keywords: Kampo medicine; blocked nose; coronavirus disease; kakkontokasenkyushin’i; olfactory disorder
Mesh:
Substances:
Year: 2021 PMID: 34108344 DOI: 10.1620/tjem.254.71
Source DB: PubMed Journal: Tohoku J Exp Med ISSN: 0040-8727 Impact factor: 1.848